How to Invest in Biotech
Short answer
You can invest in biotech by buying the individual stocks that fit the thesis (VRTX, REGN, GILD...), holding an ETF proxy like IBB or XBI, or building a focused biotech basket in Walnut. The biotech theme runs from large, cash-generative leaders (Vertex, Amgen, Gilead, Regeneron) to mid-cap innovators (Alnylam, Neurocrine, Argenx) and clinical-stage gene-editing names (CRISPR Therapeutics). IBB tilts toward the established large-cap biotech names while XBI spreads exposure across smaller, earlier-stage biotech equally. In Walnut you can describe a biotech thesis to the AI assistant and turn it into a basket of biotech stocks with target weights you approve.
How does biotech work?
Biotech companies use living systems, cells, proteins, DNA, and RNA, to create medicines and diagnostic tools. A typical biotech moves a candidate from lab research through preclinical testing and then Phase 1, 2, and 3 human trials before seeking regulatory approval. Each stage is expensive and uncertain, so many biotech firms burn cash for years before a product reaches the market. The biotech theme captures both the firms still in that pipeline phase and those that have already turned approved drugs into revenue.
How do biotech companies make money?
Profitable biotech companies make money by selling approved therapies, often patent-protected drugs that command high prices for serious or rare conditions. Names like Vertex (cystic fibrosis), Gilead (HIV and liver disease), and Amgen (a broad drug portfolio) generate large, recurring product revenue. Earlier-stage biotech firms typically have little or no revenue and fund themselves through equity raises, partnerships, and milestone payments from larger drugmakers. Licensing deals and royalties are also a common revenue stream across the biotech theme.
What is the difference between biotech and pharma?
The line between biotech and pharma has blurred, but a few distinctions hold. Biotech historically refers to companies built on biological methods (genetic engineering, cell therapy, RNA), while traditional pharma often centers on chemically synthesized small-molecule drugs. Pharma giants tend to be larger, diversified, and dividend-paying, whereas biotech names are usually more focused, faster-growing, and more volatile. Many investors treat the biotech theme as the higher-risk, innovation-driven end of the broader drug-development spectrum.
What gets a stock into the Biotech theme?
A stock fits the biotech theme if its core business is discovering, developing, or commercializing biology-based therapies (drugs, gene and cell therapies, RNA medicines) or the genomic tools behind them. It leans toward research-driven biotech rather than diversified pharma or medical devices.
What stocks are in the Biotech theme?
Every public name that fits the Biotech thesis, with the rationale for inclusion. Click any ticker for the full stock guide. The basket above starts equal-weighted; you set your own target weights inside Walnut.
Vertex is a large, profitable biotech leader built on cystic fibrosis drugs and now a sickle cell gene therapy.
Regeneron pairs blockbuster products like Eylea and Dupixent with a deep antibody-based pipeline.
Gilead is a cash-generative biotech anchored in HIV and liver disease with a growing oncology arm.
Amgen is one of the original biotech giants with a broad portfolio of biologic drugs and a dividend.
Biogen is a neuroscience-focused biotech known for multiple sclerosis drugs and Alzheimer's bets.
Moderna is an mRNA-platform biotech extending beyond COVID vaccines into oncology and rare disease.
Alnylam is the leader in RNA interference (RNAi) therapies, a fast-growing mid-cap biotech.
Incyte is a mid-cap biotech centered on oncology and inflammation, led by its drug Jakafi.
BioMarin specializes in therapies for rare genetic diseases, a classic focused biotech niche.
Neurocrine Biosciences develops neurological and endocrine drugs led by its product Ingrezza.
Argenx is a fast-growing immunology biotech built around its antibody drug Vyvgart.
CRISPR Therapeutics is a gene-editing biotech behind the approved Casgevy therapy, a higher-risk innovator.
How to invest in Biotech
There are a few common ways to get biotech exposure. Buying individual stocks lets you target specific companies and theses, for example pairing large profitable leaders like Vertex, Amgen, and Regeneron with higher-risk innovators like Alnylam, Argenx, or CRISPR Therapeutics, but it concentrates risk in single trial outcomes. ETF proxies spread that risk: IBB (iShares Biotechnology) is cap-weighted and tilts toward the large-cap biotech leaders, while XBI (SPDR S&P Biotech) is equal-weight and gives small-cap, clinical-stage biotech far more influence, which makes it more volatile. ARKG is an actively managed genomics-focused fund for a narrower, higher-conviction slice of the theme.
In Walnut you can build a biotech basket without picking everything yourself. Describe your biotech thesis to the AI assistant and it proposes a set of constituents and target weights for you to review. You approve every order before anything happens, Walnut never trades for you, and the connected brokerage executes the trades. Walnut is not an investment adviser, so the proposals are a starting point for your own decisions, not personalized recommendations.
Which ETFs cover Biotech?
If you want the theme as a single ticker rather than as a basket, these are the ETFs people most commonly use. Each has trade-offs (concentration, expense ratio, sector overlap) covered in the individual ETF guides.
The bottom line on Biotech
Biotech can add high-growth, science-driven exposure to a portfolio, but it is volatile and often binary, with individual stocks swinging hard on trial results and regulatory decisions. Sizing it as a satellite position rather than a core holding is one common way investors manage that risk, and diversifying across many names (or an ETF) softens the impact of any single trial failure.
FAQ
What is the biotech theme?
+
The biotech theme groups companies whose core business is biology-driven medicine: developing and selling drugs, gene and cell therapies, RNA medicines, and the genomic tools behind them. It ranges from large, profitable leaders to clinical-stage firms whose value depends on future trial results.
Which stocks are in the biotech theme?
+
Common biotech names include Vertex (VRTX), Regeneron (REGN), Gilead (GILD), Amgen (AMGN), Biogen (BIIB), Moderna (MRNA), Alnylam (ALNY), Incyte (INCY), BioMarin (BMRN), Neurocrine (NBIX), Argenx (ARGX), and CRISPR Therapeutics (CRSP). The exact mix depends on the thesis you want the theme to express.
What is the biggest biotech stock?
+
By market value, Vertex Pharmaceuticals and Amgen are among the largest pure-play biotech companies, with Regeneron and Gilead close behind. Rankings shift over time as drug launches, trial results, and broader market moves reprice these biotech leaders.
What is the difference between IBB and XBI?
+
IBB (iShares Biotechnology) is cap-weighted, so it leans heavily toward large-cap biotech leaders like Amgen, Gilead, and Vertex. XBI (SPDR S&P Biotech) is equal-weight, giving small and clinical-stage biotechs much more influence, which makes XBI more volatile but more sensitive to early-stage breakthroughs.
How do I invest in biotech?
+
You can buy individual biotech stocks, hold a biotech ETF like IBB, XBI, or ARKG, or build a focused biotech basket. In Walnut you describe a biotech thesis to the AI assistant, review the proposed constituents and weights, and approve the orders before your connected brokerage executes them.
Is biotech a good investment?
+
Biotech can offer strong growth from innovation in drugs and gene therapy, but it is volatile and trial outcomes can be binary, so the right fit depends on your goals and risk tolerance. Walnut is not an investment adviser, and this is descriptive information rather than a recommendation to buy or sell any biotech stock.
Why is biotech so volatile?
+
Biotech is often binary because a single clinical trial readout or FDA decision can validate or sink a company's lead drug. Smaller, clinical-stage biotechs can move 20% or more in a day on such news, which is why diversification or an ETF is a common way investors manage the theme's risk.
What is the difference between biotech and pharma?
+
Biotech generally refers to companies built on biological methods like genetic engineering, cell therapy, and RNA, while pharma often centers on chemically synthesized small-molecule drugs. Pharma firms tend to be larger, diversified, and dividend-paying, whereas biotech names are usually more focused, faster-growing, and more volatile.
How is biotech different from broad healthcare?
+
Broad healthcare includes insurers, hospitals, medical devices, distributors, and diversified pharma, while biotech is the narrower, science-driven slice focused on developing new therapies. That makes the biotech theme higher-growth and higher-risk than a diversified healthcare allocation.
Can I build a biotech basket in Walnut?
+
Yes. You can describe your biotech thesis to Walnut's AI assistant, which proposes a basket of biotech constituents and target weights. You approve every order, Walnut never trades on its own, and your connected brokerage executes the trades you confirm.
Build the Biotech basket in Walnut
Walnut's AI assistant takes the thesis above, proposes 5 to 6 constituents with target weights, and lets you fund the basket through your existing broker. You approve every order; we never trade on your behalf.
Other themes
- AI infrastructure. Picks and shovels of the AI buildout: GPUs, networking, foundries, and the software platforms training the largest models.
- Data center power and cooling. The grid, switchgear, liquid cooling, and electrical contracting that AI data centers can't run without.
- Semiconductors. The full chip stack: designers, foundries, equipment makers, materials suppliers, and packaging specialists.
- Defense and modernization. Software, sensors, and specialty materials at the center of US and allied defense buildouts.
- Critical materials. Rare earths, specialty metals, and strategic materials at the center of supply chain reshoring.
Walnut is informational, not investment advice. Theme membership is descriptive, not prescriptive; nothing on this page should be read as a recommendation. Always verify current financials and your own circumstances before investing.